Levetiracetam Tablet, Film Coated
Product Images NDC 51079-821

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 51079-821). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mylan Institutional Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Formula Calculation For Patients With Renal Impairment (A518c4f5 8b66 4770 B971 3534d581ca99 02)

Formula Calculation For Patients With Renal Impairment (A518c4f5 8b66 4770 B971 3534d581ca99 02)
This appears to be a formula or equation for calculating weight based on age, as well as a formula for calculating CLer (presumably some measure of renal function) based on gender. The last line appears to refer to a serum creatinine measurement, though it is unclear how it fits into the equations. Without additional context or explanation, the significance and proper use of this text is not available.*
FDA Label Image

Then Clcr Is Adjusted For Body Surface Area (bsa) As Follows (A518c4f5 8b66 4770 B971 3534d581ca99 03)

Then Clcr Is Adjusted For Body Surface Area (bsa) As Follows (A518c4f5 8b66 4770 B971 3534d581ca99 03)
FDA Label Image

Levetiracetam Structural Formula (A518c4f5 8b66 4770 B971 3534d581ca99 04)

Levetiracetam Structural Formula (A518c4f5 8b66 4770 B971 3534d581ca99 04)
FDA Label Image

Levetiracetam Oral Solution Weight-based Dosing Calculation For Pediatric Patients (Image 01)

Levetiracetam Oral Solution Weight-based Dosing Calculation For Pediatric Patients (Image 01)
FDA Label Image

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 02)

Figure 1: Responder Rate (≥ 50% Reduction From Baseline) In Study 1 (Image 02)
FDA Label Image

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 03)

Figure 2: Responder Rate (≥ 50% Reduction From Baseline) In Study 2: Period A (Image 03)
FDA Label Image

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 04)

Figure 3: Responder Rate (≥ 50% Reduction From Baseline) In Study 3 (Image 04)
The text describes statistical data related to the percentage of patients in a study. There are two percentages mentioned, 39.4% and 144%. The word "placebo" is mentioned along with the number 109, and a statement indicating that there was a statistically significant difference between the placebo and another group. More context is needed to fully understand the study and its results.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 05)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Image 05)
This is a clinical trial or study in which the percentage of patients is presented. 44.6% has been highlighted and indicates that this percentage is significant compared to the placebo group, which had 19.6% of patients. The study had a sample size of 97 individuals in the placebo group.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 06)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Image 06)
This is a report on statistics of a clinical trial. The percentage of improvement with respect to the treatment is 43.1%, while with the placebo it is 19.6%. A certain medication or placebo called "5 Leveraceam Tabis" was used in this trial. There was a statistically significant improvement observed with the medication compared to the placebo.*
FDA Label Image

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 07)

Figure 6: Responder Rate (≥ 50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Image 07)
FDA Label Image

Levetiracetam 500 mg Tablets Unit Carton Label (Image 08)

Levetiracetam 500 mg Tablets Unit Carton Label (Image 08)
This is a description of a medication called Levetiracetam, which comes in the form of tablets that are coated and contain 500mg of the active ingredient. The medication is only available with a prescription and comes in a bottle of 100 tablets. The usual dosage is not given but can be found in the accompanying prescription information and medication guide. The medication should be stored at room temperature between 20° to 25°C. It is manufactured by Mylan Pharmaceuticals Inc. and has an NDC code of 51079-821-20. It is a USP-controlled medication.*
FDA Label Image

Serialized Unit Carton (Image 09)

Serialized Unit Carton (Image 09)
This is a warning label on a drug package, indicating that the unit-dose packaging is not designed to be child-resistant and should be used only by adults in institutional settings. The label advises users to keep the medication out of the reach of children and notes that the container provides light-resistance. The package also includes a window displaying the lot number and expiration date. The brand of the medication is Mylan, and the company is located in Rockford, IL, USA. There is also a numerical code of 300000 107 present.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.